Author

Veronica Steri

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USAPrimary ORCID profile (0000-0003-2499-6618 · 9 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Veronica SteriiD9 papers · University of California, San Francisco

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Beatrice GiniiD· 1 shared Carlos Gomez· 1 shared Collin M. Blakely· 1 shared D. Lucas Kerr· 1 shared Dora Barbosa· 1 shared Lisa Tan· 1 shared Patrick R. Halliday· 1 shared Paul Allegakoen· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Beatrice GiniORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer

Beatrice Gini, Philippe Gui, Wei Wu, D. Lucas Kerr, Lisa Tan, Dora Barbosa, Victor Olivas, Paul Allegakoen, Carlos Gomez, Patrick R. Halliday, Sarah Elmes, Veronica Steri, Turja Chakrabarti, Trever G. Bivona, Collin M. Blakely

This study shows that CDK4/6 upregulation causes DNA replication stress and genomic instability, leading to resistance to EGFR inhibitors in lung cancer, and suggests combining CDK4/6 and EGFR inhibitors as a treatment.

bioRxiv · Mar 12, 2024 · PreprintCancer Biology